Results 171 to 180 of about 79,680 (194)

HMGCR and Rosuvastatin Regulates GLP-1 Secretion and Expression-A Translational Study.

J Clin Endocrinol Metab
Miskelly MG, Lindqvist A, Jujić A, Hamilton A, Cowan E, Raikundalia S, Dutius Andersson AM, Nergård BJ, Del Giudice R, Kryvokhyzha D, Nilsson PM, Holst JJ, Torekov SS, Lagerstedt JO, Gomez MF, Eliasson L, Mulder H, Hedenbro J, Magnusson M, Wierup N.   +19 more
europepmc   +1 more source

GLP-1 Receptor Agonists in Brazil: Landscape of Consumption, Safety and Regulation. [PDF]

Diabetes Obes Metab
Hurtado RL, Amato AA, de Luca Corrêa H, Silveira D.   +3 more
europepmc   +1 more source

Musculoskeletal Outcomes of Glucagon‐Like Peptide‐1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults

Obesity, EarlyView.
ABSTRACT Objective This study aimed to evaluate the association of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) with risks of osteoporosis, major osteoporotic fractures, and degenerative musculoskeletal disorders in nondiabetic adults with obesity compared with other obesity medications.
Jie‐Syuan Wu, Lee‐Yuan Lin, Jia‐Wei Sun, Wei‐Ting Yu, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +5 more
wiley   +1 more source

Nutritional Vulnerability in RYGB Unmasked by GLP-1 Therapy. [PDF]

ACG Case Rep J
Madej J, Gonzaga ER, Naveed M.
europepmc   +1 more source

Use of Glucagon‐Like Peptide‐1 Receptor Agonists in Danish Adolescents and Young Adults 2018–2025

Obesity, EarlyView.
ABSTRACT Objective Use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) has increased rapidly following approval for obesity treatment, but data on their use in younger populations remain limited. We examined trends in GLP‐1RA use among 12– to 24‐year‐olds in Denmark during 2018–2025.
Helene Kildegaard, Jacob Harbo Andersen, Rebecca Kofod Vinding, Julie Tonsgaard Kloppenborg, Anton Pottegård   +4 more
wiley   +1 more source

Interpreting Pregnancy Risk After GLP-1 Receptor Agonists Discontinuation. [PDF]

Diabetes Obes Metab
Scairati R, Newman C, Dunne FP, Colao A.
europepmc   +1 more source

Six‐ and Twelve‐Month Changes in Body Composition and 24‐h Energy Expenditure After a Very Low‐Calorie Ketogenic Diet

Obesity, EarlyView.
ABSTRACT Objective This study assessed changes in body composition and 24‐h energy metabolism at 6 and 12 months after initiation of a 1‐month very low‐calorie ketogenic diet (VLCKD) in women with obesity. Methods Seventeen women with obesity who completed a 1‐month VLCKD underwent a 4‐week transition phase with carbohydrate reintroduction, followed by
Alessio Basolo, Paolo Piaggi, Valentina Angeli, Paola Fierabracci, Chiara Bologna, Giordano Paolucci, Guido Salvetti, Luca Chiovato, Jonathan Krakoff, Alberto Landi, Ferruccio Santini   +10 more
wiley   +1 more source

GLP-1 receptor agonists and conscious sedation. [PDF]

Interv Pain Med
Holder EK, Ni A, Levi D, International Pain and Spine Intervention Society's Patient Safety Committee.   +3 more
europepmc   +1 more source

SURMOUNT‐REAL UK: A Pragmatic Randomized Clinical Trial to Assess the Effectiveness of Tirzepatide in Adults With Obesity

Obesity, EarlyView.
ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter, Julie Mount, J. Martin Gibson, Joanne Webb, Cheryl Marler, Catherine Reed, Mugdha Gore, Wenyu Ye, Elisa Gomez Valderas, John Wilding, Naveed Sattar, Melanie J. Davies, Kamlesh Khunti, Richard Haynes, Rachel L. Batterham   +14 more
wiley   +1 more source

The promise of GLP-1 receptor agonists for neurodegenerative diseases. [PDF]

J Clin Invest
Athauda D, Greig NH, Meissner WG, Foltynie T, Gandhi S.   +4 more
europepmc   +1 more source